Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...
From its original U.S. home base in Deerfield, Illinois, Lundbeck now plans to relocate its local headquarters to Greater ...
In just over a month, the FDA has cleared not one, but two treatments for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic condition that causes soft tissues to turn to bone. | Mirum ...
Bristol Myers Squibb plans another major round of job cuts in New Jersey, bringing the number of total layoffs the company ...
Eli Lilly and InnoCare Pharma inked a multi-target deal potentially worth $3.35 billion. The FDA has doled out the first approval for a novel cancer drug from a Korean company. | Eli Lilly and ...
Boehringer Ingelheim is bidding adieu to its biologics contract manufacturing unit in China, inking a small-scale deal that gives local developer Raas Blood Products an established production base for ...
Much like GSK (formerly GlaxoSmithKline) and the once Sanofi-Aventis (now just Sanofi), Novo Nordisk is slimming down its ...
Eli Lilly is sharpening its competitive edge in the crowded oral SERD arena as the FDA has approved a combination of its ...
The FDA came to Elevar Therapeutics bearing gift ahead of the mid-autumn festival. | The FDA has greenlighted Elevar’s FGFR2-selective inhibitor Lyrfigtu in bile duct cancer, making it the first novel ...
Par Health has issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection ...
Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to ...
Otsuka ICU Medical, a joint venture from Japan’s Otsuka Pharmaceutical Factory, issued a voluntary recall of one lot of 0.9% sodium chloride injection for IV due to a possible mix-up of labels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results